Hemant Surgical Industries (BSE: HSIL) had a P/E of 42.1× on 6 Nov 2026, above the industry P/E of 34.9×. It earns ROCE of 20% and ROE of 18%, and sales and net profit grew 28% and 34% a year over 3 years. Debt is 0.36× equity. It is listed on an SME platform with a market cap of ₹914 Cr, ranked 4th of 9 Medical Devices companies by market cap; the shares rose 117% over the past year.
- ₹630.00
- ₹650.00
- ₹603.00
- ₹630.00
- 12.8K
Health check
- ReturnsAhead
+117.2% over a year, better than 7 of 7 peers.
- Price tagPricier
P/E 42.1 vs industry 34.9.
- GrowthSteady
Sales +28.4%, profit +33.5% a year over 3 years.
- ProfitabilityAverage
ROCE 19.5% vs peer median 12.9%.
- Balance sheetFair
Debt 0.36× equity, interest covered 6.9×, Piotroski 4 of 9.
- Red flagsNone found
No warning signs in the headline numbers.
Small cap
Moves with the market
Key metrics
- Market cap
- ₹914 Cr
- Small cap
- P/E
- 42.1
- Industry 34.9
- Price to book
- 5.95
- Peers 2.85
- Dividend yield
- 0.00%
- ROE
- 18.1%
- Peers 10.7%
- ROCE
- 19.5%
- Peers 12.9%
- Debt to equity
- 0.36
- Debt ₹50 Cr
- EPS (TTM)
- ₹14.94
- OPM (TTM)
- 10.0%
- Net margin 7.8%
- Sales growth
- +189.4%
- Latest quarter vs a year ago
- Profit growth
- +192.6%
- Latest quarter vs a year ago
- Price to sales
- 3.94
- EV/EBITDA 36.5
Strengths and risks
Strengths
- Return on equity of 18.1%.
- Quarterly profit up 192.6% on a year ago.
- Quarterly sales up 189.4% on a year ago.
About Hemant Surgical Industries
Hemant Surgical Industries Limited manufactures, assembles, imports, and exports, markets, distributes surgical products, healthcare products & medical equipment and pharmaceutical products for the healthcare sector in India and internationally. The company offers healthcare & surgical disposables, including jms meditape, infusion sets, scap vein set, blood transfusion set, pediatric iv, burette set, safecath silicone foley catheter, endotracheal tube,…
- Headquarters
- Mumbai
- Employees
- 109
- Sector
- Healthcare
- ISIN
- INE0GYI01028
- Website
- hemantsurgical.com
Price range
- Avg volume (3M)
- 33.3K
- 1-year return
- plus 117.2%
- From 52-week high
- minus 7.4%
Peers · Medical Devices
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MOLBIOMolbio Diagnostics | 1,339.30 | minus 4.57% | 15,434 | 92.6 | 12.91 | 16.5% | 15.6% | 20.4% | 63.7% | – | 0.00% | plus 28.6% |
| SMTSahajanand Medical Technologies | 525.95 | plus 7.83% | 5,346 | 77.3 | 7.42 | 13.3% | 10.7% | 8.4% | – | – | 0.00% | plus 39.3% |
| FISCHERFischer Medical Ventures | 24.30 | minus 2.88% | 1,698 | 10.4 | 4.08 | 12.5% | 8.9% | 12.5% | 1097.3% | – | 0.21% | minus 73.4% |
| HSILHemant Surgical Industries | 628.65 | minus 0.21% | 914 | 42.1 | 5.95 | 19.5% | 18.1% | 10.0% | 28.4% | 33.5% | 0.00% | plus 117.2% |
| UNIVPHOTOUniversus Photo Imagings | 480.00 | minus 1.49% | 525 | – | 0.65 | −9.5% | −9.5% | 5.4% | −24.3% | – | 0.00% | plus 74.8% |
| NURECANureca | 302.30 | minus 0.30% | 302 | 61.4 | 1.53 | – | 2.5% | 8.3% | 9.7% | – | 0.00% | plus 17.4% |
| EARKARTEarkart | 111.00 | minus 5.13% | 153 | 27.8 | 2.37 | 12.1% | 11.7% | 15.3% | 23.2% | 55.5% | 0.00% | minus 48.5% |
| CHOKSIChoksi Asia | 210.35 | minus 0.71% | 120 | 23.1 | 2.85 | 18.4% | 13.5% | 14.5% | 309.2% | – | 0.00% | plus 99.0% |
| Median of 7 peers | – | −1.49% | 525 | 44.6 | 2.85 | 12.9% | 10.7% | 12.5% | 43.4% | 55.5% | 0.00% | 28.6% |
Quarterly results
This company doesn’t report these figures in a format we can read yet.
Profit & loss
- Sales CAGR 3Y
- +28.4%
- Profit CAGR 3Y
- +33.5%
- ROE
- 18.1%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 109 | 106 | 105 | 231 | |
| – | minus 3.2% | minus 0.1% | +119.2% | |
| 98.6 | 94.7 | 94.5 | 207 | |
| 10.6 | 10.9 | 10.9 | 23.9 | |
| 9.7% | 10.3% | 10.4% | 10.3% | |
| 2.3 | 3 | 1.3 | 2.7 | |
| 2 | 1 | 2.2 | 4 | |
| 0.8 | 1 | 1.4 | 1.5 | |
| −0.1 | 0.9 | 1.8 | 2.5 | |
| 10.1 | 12.8 | 10.5 | 23.6 | |
| 24.1% | 23.3% | 23.2% | 22.9% | |
| 7.6 | 9.8 | 8 | 18.2 | |
| – | +28.3% | minus 17.9% | +126.2% | |
| 7.32 | 9.85 | 7.70 | – |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 7.7 | 10.4 | 10.4 | 13 | |
| 15.7 | 44.4 | 52.7 | 125 | |
| 7.1 | 6.8 | 31 | 49.7 | |
| 34.2 | 35 | 54.1 | 87 | |
| 64.7 | 96.6 | 148 | 274 | |
| 13.2 | 17.7 | 51.8 | 53.4 | |
| – | – | 11.9 | – | |
| 0.4 | 4.9 | 1.3 | 4.9 | |
| 8.5 | 13.2 | 7.1 | 31.5 | |
| 42.7 | 60.9 | 76.3 | 184 | |
| 64.7 | 96.6 | 148 | 274 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 6.3 | −7.6 | 4.6 | −32 | |
| −3 | −9 | −30.3 | −3 | |
| −0.7 | 21.2 | 21.9 | 69.3 | |
| 2.6 | 4.7 | −3.8 | 34.3 | |
| −3.9 | −5.5 | −37.6 | −9.4 | |
| 2.4 | −13.1 | −32.9 | −41.4 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders. Institutions hold about 17.2% (Yahoo estimate).
Major shareholders
Filings & events
News
No recent news coverage found.